Lots of viruses have disappeared before. But experts think COVID will stay with us for a long time to come.
Rigor académico, oficio periodístico
Artículos sobre Vaccines
Mostrando 421 - 440 de 783 artículos
We’re on the road again. Getting enough COVID-19 vaccine to where it’s needed in a given time frame is the next logistical hurdle.
Budget cuts and outsourcing content have affected the amount and quality of science journalism. Scientists should learn to communicate their own findings directly and clearly to the public.
Several new studies show our immune responses to the virus can last at least eight or nine months, and probably longer.
There are arguments both for and against making vaccination compulsory.
There is now a third vaccine that prevents COVID-19 infections. It isn’t quite as effective as the other two vaccines but it has advantages that may make it the frontrunner.
Amid good news on the vaccine trial-front, Australia must think more carefully about how a national roll-out would work.
COVID-19 vaccines are at risk of being undermined by vaccine hesitancy. Pharma must take steps to ensure transparency in data monitoring committees and trial data to build public trust in vaccines.
In the disturbing scenario of human-to-mink-to-human COVID-19 transmission, the virus may mutate in mink prior to re-infecting people. That possibility makes vaccine design even more crucial.
Because Pfizer-BioNTech and Moderna vaccines have been developed in record time, many wonder whether companies cut corners or compromised safety.
Inaction over the next few months could cost tens of thousands of lives. Here are things you should do now to stay safe and to stop the spread of the coronavirus.
Pfizer and BioNTech have announced 95% efficacy for their mRNA vaccine, having met the final target they need to before seeking regulatory approval.
Two pharma companies have announced early COVID-19 vaccine trial results with over 90 per cent effectiveness. What does that mean for getting back to normal?
Asking these four questions can help us identify good news when we see it, be more critical of news reports, or delay our judgement until we have more information.
There are two new COVID-19 vaccines that appear to be more than 90% effective. But what are these vaccines, and how are they different from those used previously?
A private market should have no place in the rollout of a COVID vaccine.
The funding, procurement, storage and distribution of a vaccine present huge challenges to all governments, including New Zealand’s.
As viruses are transmitted from person to person they are constantly mutating and replicating. Could the SARS-CoV-2 virus evolve to evade the new vaccines that have just been developed?
Distributing a vaccine is a bit like boarding a plane — we can’t all board at the same time. So who gets priority? There are a few reasons we should consider vaccinating older people first.
The federal government has concluded a $1 billion agreement for a new high-tech manufacturing facility in Melbourne which would produce pandemic influenza vaccines as well as antivenoms.
Principales colaboradores
-
Professorial Fellow, University of Canberra
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Professor of Medicine, University of Virginia
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Associate Professor of Biology, Rochester Institute of Technology
-
Dean Faculty of Health Sciences and Professor of Vaccinology at University of the Witwatersrand; and Director of the SAMRC Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand
-
Professor of Immunology, Vice-Chancellors Distinguished Professorial Fellow, Head of Immunology and Translational Research, Victoria University
-
Professor of Microbiology, School of Medicine, University of Washington
-
Lecturer in Virology, Queen's University Belfast
-
Professor of Immunology, RMIT University
-
Assistant Professor of Political Science, Oklahoma State University
-
Associate Professor, Discipline of Childhood and Adolescent Health, University of Sydney
-
Professor, Discipline of Paediatrics and Child Health, University of Sydney
-
Senior Lecturer; MD, Victoria University
-
Associate Professor and ARC Future Fellow, The University of Western Australia
